CSPC Pharmaceutical Group Limited Cash Flow-to-Debt Ratio
CSPC Pharmaceutical Group Limited cash flow-to-debt ratio. CSPC Pharmaceutical Group Limited (CVG) has a Cash Flow-to-Debt Ratio of 0.25x as of June 2020, meaning its operating cash flow of €2.16 Billion could theoretically repay 0% of its total liabilities (€8.46 Billion) in one year. Check CSPC Pharmaceutical Group Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CSPC Pharmaceutical Group Limited (2013–2025)
Cash flow-to-debt ratio of CSPC Pharmaceutical Group Limited from 2013 to 2025. Historical debt coverage capacity for CSPC Pharmaceutical Group Limited across 13 annual periods. Check how aggressively does CSPC Pharmaceutical Group Limited reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CSPC Pharmaceutical Group Limited Cash Flow-to-Debt Ratio by Year (2013–2025)
CSPC Pharmaceutical Group Limited cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for CSPC Pharmaceutical Group Limited. For the full cash flow conversion analysis, see CVG cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | €5.83 Billion | €12.15 Billion | ▲ +11.4% |
| 2024 | 0.43x | €4.53 Billion | €10.52 Billion | ▲ +16.2% |
| 2023 | 0.37x | €4.18 Billion | €11.26 Billion | ▼ -50.7% |
| 2022 | 0.75x | €7.63 Billion | €10.13 Billion | ▲ +28.5% |
| 2021 | 0.59x | €4.64 Billion | €7.91 Billion | ▼ -39.4% |
| 2020 | 0.97x | €6.74 Billion | €6.97 Billion | ▲ +73.8% |
| 2019 | 0.56x | €3.78 Billion | €6.80 Billion | ▲ +12.5% |
| 2018 | 0.49x | €3.80 Billion | €7.67 Billion | ▼ -22.9% |
| 2017 | 0.64x | €3.29 Billion | €5.13 Billion | ▼ -10.0% |
| 2016 | 0.71x | €2.92 Billion | €4.09 Billion | ▲ +49.8% |
| 2015 | 0.48x | €2.25 Billion | €4.73 Billion | ▲ +14.6% |
| 2014 | 0.42x | €1.81 Billion | €4.35 Billion | ▲ +134.6% |
| 2013 | 0.18x | €814.86 Million | €4.60 Billion | — |